This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Prognosis

Authoring team

Although Mycosis Fungoides/Szesary syndrome are generally considered incurable conditions, it is important to recognize that the majority of patients have an indolent form of the disease and will live for many years

  • estimated that 65% to 85% of patients with MF have stage IA or IB disease
    • the majority of patients with early-stage disease (stages IA, IB, and IIA) do not progress to more advanced-stage disease
      • patients presenting with isolated patch or plaque disease (T1-T2) have a median survival of more than 12 years

  • stage IIB, III, IVA
    • patients with advanced-stage disease (stages IIB, III, and IVA) with tumors, erythroderma, and lymph node or blood involvement but no visceral involvement has a median survival of 5 years from time of presentation

  • stage IVB
    • patients with visceral involvement are rare (stage IVB) and have a median survival of only 2.5 years or less

Reference:

  • Kim YH, Liu HL, Mraz-Gernhard S, Varghese A, Hoppe RT. Long-term outcome of 525 patients with mycosis fungoides and Sezary syndrome: clinical prognostic factors and risk for disease progression. Arch Dermatol. 2003;139(7):857-866.

Create an account to add page annotations

Add information to this page that would be handy to have on hand during a consultation, such as a web address or phone number. This information will always be displayed when you visit this page

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.